# Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

> **NCT04535999** · PHASE4 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 16 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Secukinumab Auto-Injector

## Key facts

- **NCT ID:** NCT04535999
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-07
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04535999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04535999, "Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04535999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*